TY - JOUR
T1 - US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema
AU - Busse, Paula J.
AU - Christiansen, Sandra C.
AU - Riedl, Marc A.
AU - Banerji, Aleena
AU - Bernstein, Jonathan A.
AU - Castaldo, Anthony J.
AU - Craig, Timothy
AU - Davis-Lorton, Mark
AU - Frank, Michael M.
AU - Li, H. Henry
AU - Lumry, William R.
AU - Zuraw, Bruce L.
N1 - Funding Information:
Conflicts of interest: P. J. Busse is a consultant for Takeda, Pharming, Pearl Therapeutics, BioCryst, CVS Health, GSK, Astra Zeneca, resTORbio, and Legal consulting. S. C. Christiansen is a consultant for CSL Behring, BioCryst, Takeda, and Fresenius Kabi. M. A. Riedl is a consultant for Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, and Takeda; and received grants from BioCryst, CSL Behring, Takeda, and Ionis. A. Banerji is a consultant for Takeda, CSL, BioCryst, Pharming, Pharvaris, and KalVista; and received grants from Takeda and BioCryst. J. A. Bernstein is a consultant for Shire/Takeda, CSL Behring, Pharming, BioCryst, KalVista, and Ionis; and is a speaker for Shire/Takeda, CSL Behring, and Pharming. A. J. Castaldo declares no relevant conflicts of interest. T. Craig received grants from Takeda, CSL Behring, BioCryst, and Grifols; and is a consultant for Takeda, CSL Behring, Grifols, Pharming, BioCryst, and Ionis. M. Davis-Lorton is a consultant for CSL Behring, Pharming, and Takeda. H. H. Li is a consultant for Takeda, CSL Behring, Pharming, and BioCryst. W. R. Lumry is a consultant for Takeda, Pharming, BioCryst, CSL Behring, KalVista, BioMarin, and Fresenius Kabi; and received grants from CSL Behring, Takeda, BioCryst, Ionis, and KalVista. B. L. Zuraw is a consultant for Adverum, Attune, BioCryst, CSL Behring, KalVista, Pharming, Takeda, and Fresenius Kabi; and received grant from Ionis.
Publisher Copyright:
© 2020
PY - 2021/1
Y1 - 2021/1
N2 - Scientific and clinical progress together with the development of effective novel therapeutic options has engendered multiple important changes in the diagnosis and management of hereditary angioedema (HAE). We now update and extend the 2013 United States Hereditary Angioedema Association Medical Advisory Board guidelines for the treatment and management of HAE. The guidelines are based on a comprehensive literature review with recommendations indicating both the strength of our recommendation and the quality of the underlying evidence. Guidelines are provided regarding the classification, diagnosis, on-demand treatment, prophylactic treatment, special considerations for women and children, development of a comprehensive management and monitoring plan, and assessment of burden of illness for both HAE due to C1 inhibitor deficiency and HAE with normal C1 inhibitor. Advances in HAE treatment now allow the development of management plans that can help many patients with HAE lead a normal life. Achieving this goal requires that physicians be familiar with the diagnostic and therapeutic transformations that have occurred in recent years.
AB - Scientific and clinical progress together with the development of effective novel therapeutic options has engendered multiple important changes in the diagnosis and management of hereditary angioedema (HAE). We now update and extend the 2013 United States Hereditary Angioedema Association Medical Advisory Board guidelines for the treatment and management of HAE. The guidelines are based on a comprehensive literature review with recommendations indicating both the strength of our recommendation and the quality of the underlying evidence. Guidelines are provided regarding the classification, diagnosis, on-demand treatment, prophylactic treatment, special considerations for women and children, development of a comprehensive management and monitoring plan, and assessment of burden of illness for both HAE due to C1 inhibitor deficiency and HAE with normal C1 inhibitor. Advances in HAE treatment now allow the development of management plans that can help many patients with HAE lead a normal life. Achieving this goal requires that physicians be familiar with the diagnostic and therapeutic transformations that have occurred in recent years.
KW - Bradykinin
KW - C1 inhibitor
KW - Hereditary angioedema
KW - Management
KW - On-demand treatment
KW - Prophylactic treatment
UR - http://www.scopus.com/inward/record.url?scp=85096147942&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2020.08.046
DO - 10.1016/j.jaip.2020.08.046
M3 - Article
C2 - 32898710
AN - SCOPUS:85096147942
SN - 2213-2198
VL - 9
SP - 132-150.e3
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 1
ER -